Use of sacubitril/valsartan in patients with heart failure: evidence from the real world

References

• Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure Association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure: endorsed by the Canadian heart failure society, heart failure association of India, cardiac society of Australia and New Zealand, and Chinese heart failure Association. Eur J Heart Fail. 2021;23(3):352–380. doi: 10.1002/ejhf.2115
   PubMed Web of Science ®Google Scholar
• Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–3287. doi: 10.1093/cvr/cvac013
   PubMed Web of Science ®Google Scholar
• Bragazzi NL, Zhong W, Shu J, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol. 2021;28(15): 1682–1690. doi: 10.1093/eurjpc/zwaa147
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart Association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e895–e1032. doi: 10.1161/CIR.0000000000001063
   PubMed Web of Science ®Google Scholar
• Iovanovici DC, Bungau SG, Vesa CM, et al. Reviewing the modern therapeutical options and the outcomes of sacubitril/valsartan in heart failure. Int J Mol Sci. 2022;23(19): 11336. doi: 10.3390/ijms231911336
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al.; PARADIGM-HF investigators and committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi: 10.1056/NEJMoa1409077
   PubMed Web of Science ®Google Scholar
• Tian Q, Xiong Z, Fan H, et al. The Efficacy and safety of sacubitril-valsartan for the treatment of heart failure in adults: a meta-analysis. Ann Pharmacother. 2023;57(4):441–449. doi: 10.1177/10600280221112158
   PubMed Web of Science ®Google Scholar
• Proudfoot C, Studer R, Rajput T, et al. Real-world effectiveness and safety of sacubitril/valsartan in heart failure: a systematic review. Int J Cardiol. 2021;331: 164–171. doi: 10.1016/j.ijcard.2021.01.061
   PubMed Web of Science ®Google Scholar
• Rahhal A, Kasem M, Orabi B, et al. Effectiveness of sacubitril/valsartan in heart failure with reduced ejection fraction using real-world data: an updated systematic review and meta-analysis. Curr Probl Cardiol. 2023;48(1): 101412. doi: 10.1016/j.cpcardiol.2022.101412
   PubMed Web of Science ®Google Scholar
• Liu F, Panagiotakos D Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol. 2022;22(1): 287. doi: 10.1186/s12874-022-01768-6
   PubMed Web of Science ®Google Scholar
• Chen WW, Jiang J, Gao J, et al. Efficacy and safety of low-dose sacubitril/valsartan in heart failure patients: a systematic review and meta-analysis. Clin Cardiol. 2023;46(3): 296–303. doi: 10.1002/clc.23971
   PubMed Web of Science ®Google Scholar
• Morales-Parra MP, Salazar-Niño JF, Caycedo-González LA, et al. Experiencia con sacubitril/valsartán en una clínica de falla cardiaca. Rev Colomb Cardiol. 2020;27(1):7–12. doi: 10.1016/j.rccar.2018.10.009
   Google Scholar
• Muñoz OM, García ÁA, Fernández-Ávila D, et al. Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias: evaluación del riesgo cardiovascular. Rev Colomb Cardiol. 2015;22(6): 263–269. doi: 10.1016/j.rccar.2015.04.009
   Google Scholar
• Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1): 111–188. doi: 10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Park JJ, Lee SE, Cho HJ, et al. Real-world usage of sacubitril/valsartan in Korea: a multi-center, retrospective study. Int J Heart Fail. 2022;4(4): 193–204. doi: 10.36628/ijhf.2022.0015
   PubMedGoogle Scholar
• Chen W, Liu Y, Tang L, et al. Clinical characteristics, prescription patterns, and persistence associated with sacubitril/valsartan adoption: a STROBE-compliant study. Medicine (Baltimore). 2021;100(30):e26809. doi: 10.1097/MD.0000000000026809
   PubMed Web of Science ®Google Scholar
• Mapelli M, Salvioni E, de Martino F, et al. Sacubitril/Valsartan use in a real-world population of patients with heart failure and reduced ejection fraction. J Cardiovasc Med (Hagerstown). 2020;21(11):882–888. doi: 10.2459/JCM.0000000000001018
   PubMed Web of Science ®Google Scholar
• Du AX, Westerhout CM, McAlister FA, et al. Titration and tolerability of sacubitril/valsartan for patients with heart failure in clinical practice. J Cardiovasc Pharmacol. 2019;73(3): 149–154. doi: 10.1097/FJC.0000000000000643
   PubMed Web of Science ®Google Scholar
• Chen W, Liu Y, Li Y, et al. Sacubitril/Valsartan improves cardiac function in Chinese patients with heart failure: a real-world study. ESC Heart Fail. 2021;8(5):3783–3790. doi: 10.1002/ehf2.13491
   PubMed Web of Science ®Google Scholar
• Di Lenarda A, Di Gesaro G, Sarullo FM, et al. Sacubitril/Valsartan in heart failure with reduced ejection fraction: real-world experience from Italy (the REAL.IT study). J Clin Med. 2023;12(2):699. doi: 10.3390/jcm12020699
   PubMed Web of Science ®Google Scholar
• Cheang I, Shi S, Lu X, et al. Efficacy and dosage pattern of sacubitril/valsartan in Chinese heart failure with reduced ejection fraction patients. J Cardiovasc Transl Res. 2022;15(5): 1192–1202. doi: 10.1007/s12265-022-10236-x
   PubMed Web of Science ®Google Scholar
• Fu M, Vedin O, Svennblad B, et al. Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants. ESC Heart Fail. 2020;7(6):3633–3643. doi: 10.1002/ehf2.12883
   PubMed Web of Science ®Google Scholar
• Visco V, Radano I, Campanile A, et al. Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF. ESC Heart Fail. 2022;9(5): 2909–2917. doi: 10.1002/ehf2.13982
   PubMed Web of Science ®Google Scholar
• Rattanavipanon W, Sotananusak T, Yamaae F, et al. Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis. BMC Cardiovasc Disord. 2021;21(1):324. doi: 10.1186/s12872-021-02145-9.
   PubMed Web of Science ®Google Scholar
• Wang C, Lin Z, Miao D, et al. Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study. ESC Heart Fail. 2023;10(3): 1961–1971. doi: 10.1002/ehf2.14367
   PubMed Web of Science ®Google Scholar
• Savarese G, Bodegard J, Norhammar A, et al. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Eur J Heart Fail. 2021;23(9): 1499–1511. doi: 10.1002/ejhf.2271
   PubMed Web of Science ®Google Scholar
• Hsiao FC, Wang CL, Chang PC, et al. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: real-world experience from Taiwan. J Cardiovasc Pharmacol Ther. 2020;25(2): 152–157. doi: 10.1177/1074248419872958
   PubMed Web of Science ®Google Scholar
• Wachter R, Fonseca AF, Balas B, et al. Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany. Eur J Heart Fail. 2019;21(5):588–597. doi: 10.1002/ejhf.1465
   PubMed Web of Science ®Google Scholar
• Vicent L, Esteban-Fernández A, Gómez-Bueno M, et al. Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry. J Cardiovasc Pharmacol. 2019;73(2): 118–124. doi: 10.1097/FJC.0000000000000641
   PubMed Web of Science ®Google Scholar
• López-Azor JC, Vicent L, Valero-Masa MJ, et al. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort. ESC Heart Fail. 2019;6(6): 1161–1166. doi: 10.1002/ehf2.12527
   PubMed Web of Science ®Google Scholar
• Ministerio de Salud y Protección Social. Resolución 2292 de 2021: Por la cual se actualizan y establecen los servicios y tecnologías de salud financiados con recursos de la Unidad de Pago por Capitación. cited 2023 Jul 1. https://www.minsalud.gov.co/Normatividad_Nuevo/Resoluci%C3%B3n%20No.%202292%20de%202021.pdf.
   Google Scholar
• Instituto Nacional de Salud. Corononavirus (COVID-19) en Colombia. [cited 2023 May 15]. https://www.ins.gov.co/Noticias/paginas/coronavirus.aspx.
   Google Scholar
• Esteban-Fernández A, Díez-Villanueva P, Vicent L, et al. Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort. Rev Esp Geriatr Gerontol. 2020;55(2):65–69. doi: 10.1016/j.regg.2019.10.002
   PubMedGoogle Scholar
• Saldarriaga C, Gallego C, Fajardo LA, et al. Multidisciplinary Heart Failure Care Program: An Experience From Colombia. Curr Prob Cardiol. 2023;48(1): 101431. doi: 10.1016/j.cpcardiol.2022.101431
   PubMed Web of Science ®Google Scholar
• Rivera-Toquica A, Saldarriaga-Giraldo C, Echeverría LE, et al. Actualización 2022 del Consenso colombiano de insuficiencia cardíaca con fracción de eyección reducida: Capítulo de falla cardíaca, trasplante cardíaco e hipertensión pulmonar de la Asociación Sociedad Colombiana de Cardiología y Cirugía Cardiovascular. [Internet]. 2022. [cited 2023 Nov] http://hdl.handle.net/10554/62278.
   Google Scholar
• Mapelli M, Mattavelli I, Salvioni E, et al. Looking into the kinetics of NT-proBNP and sST2 changes in patients with heart failure treated with sacubitril/valsartan: a hint to different Therapeutic pathways. Drugs R&D. 2023. doi: 10.1007/s40268-023-00438-2
   PubMed Web of Science ®Google Scholar
• Mapelli M, Mattavelli I, Paolillo S, et al. Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration. Eur J Clin Pharmacol. 2023;79(9): 1173–1184. doi: 10.1007/s00228-023-03527-y
   PubMed Web of Science ®Google Scholar
• Machado-Duque ME, Ramírez-Valencia DM, Medina-Morales DA, et al. Effectiveness and clinical inertia in the management of hypertension in patients in Colombia. J Am Soc Hypertens. 2015;9(11):878–884. doi: 10.1016/j.jash.2015.08.011
   PubMed Web of Science ®Google Scholar
• Machado-Duque ME, Ramírez-Riveros AC, Machado-Alba JE Effectiveness and clinical inertia in patients with antidiabetic therapy. Int J Clin Pract. 2017;71(6). doi: 10.1111/ijcp.12954. e12954
   Web of Science ®Google Scholar
• Girerd N, Von Hunolstein JJ, Pellicori P, et al.; EF-HF Group. Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction. ESC Heart Fail. 2022;9(4): 2063–2069. doi: 10.1002/ehf2.13929
   PubMed Web of Science ®Google Scholar
• Kuan WC, Sim R, Wong WJ, et al. Economic evaluations of guideline-directed medical therapies for heart failure with reduced ejection fraction: a systematic review. Value Health. 2023;26(10): 1558–1576. doi: 10.1016/j.jval.2023.05.011
   PubMed Web of Science ®Google Scholar
• Martins E, Pereira GS, Duarte G, et al. Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis. Expert Opin Drug Saf. 2021;20(5):577–588. doi: 10.1080/14740338.2021.1877658
   PubMed Web of Science ®Google Scholar
• Kim YS, Brar S, D’Albo N, et al. Five years of sacubitril/Valsartan-a safety analysis of randomized clinical trials and real-world pharmacovigilance. Cardiovasc Drugs Ther. 2022;36(5):915–924. doi: 10.1007/s10557-021-07210-1
   PubMed Web of Science ®Google Scholar
• Machado-Alba JE, Londoño-Builes MJ, Echeverri-Cataño LF, et al. Adverse drug reactions in Colombian patients, 2007-2013: analysis of population databases. Biomedica. 2016;36(1):59–66. doi: 10.7705/biomedica.v36i1.2781
   PubMed Web of Science ®Google Scholar